| Literature DB >> 31527875 |
Suttipong Kawilapat1,2,3, Nicolas Salvadori1,2, Nicole Ngo-Giang-Huong1,2,4, Luc Decker1,2, Suparat Kanjanavanit5, Achara Puangsombat6, Kanchana Preedisripipat7, Narong Lertpienthum8, Noppadon Akarathum9, Jutarat Mekmullica10, Ussanee Srirompotong11, Marc Lallemant1,2,4, Sophie Le Coeur1,2,4,12, Patrinee Traisathit1,13, Charline Leroi1,2, Gonzague Jourdain1,2,4.
Abstract
INTRODUCTION: The success of antiretroviral treatment (ART) programs can be compromised by high rates of patient loss to follow-up (LTFU). We assessed the incidence and risk factors of LTFU in a large cohort of HIV-infected children receiving ART in Thailand.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31527875 PMCID: PMC6748564 DOI: 10.1371/journal.pone.0222082
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Children’s characteristics at antiretroviral therapy initiation.
| Characteristics | Frequency (percentage) or median [interquartile range] | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male (n = 402) | Female (n = 471) | All children (n = 873 | ||||||||
| Age (years) | 6.8 | [2.7, 9.3] | 6.5 | [2.0, 10.0] | 6.5 | [2.4, 9.6] | ||||
| Country of birth: Thailand (n = 797) | 356 | (98%) | 425 | (98%) | 781 | (98%) | ||||
| Born in a district hospital (n = 515) | 101 | (45%) | 151 | (52%) | 252 | (49%) | ||||
| Living with relatives (n = 730) | 303 | (91%) | 362 | (91%) | 665 | (91%) | ||||
| Follow-up in the northern region of Thailand | 236 | (59%) | 296 | (63%) | 532 | (61%) | ||||
| Height-for-age Z-scores (n = 602) | -2.17 | [-3.06, -1.01] | -1.91 | [-2.86, -1.06] | -2.03 | [-3.00, -1.04] | ||||
| Height-for-age Z-scores <-2 SD | 152 | (55%) | 152 | (47%) | 304 | (51%) | ||||
| Weight-for-age Z-scores (n = 602) | -1.20 | [0.173, -0.69] | -1.19 | [-1.72, -0.59] | -1.20 | [-1.73, -0.63] | ||||
| Weight-for-age Z-scores <-2 SD | 47 | (17%) | 52 | (16%) | 99 | (16%) | ||||
| Initiated ART before 2005 | 249 | (62%) | 302 | (64%) | 551 | (63%) | ||||
| Initiate ART before enrollment to the cohort | 122 | (30%) | 138 | (29%) | 260 | (30%) | ||||
| CDC stage (n = 782) | ||||||||||
| Class N or A | 162 | (45%) | 188 | (45%) | 350 | (45%) | ||||
| Class B or C | 198 | (55%) | 234 | (55%) | 432 | (55%) | ||||
| HIV-RNA load (log10 copies/mL) (n = 520) | 5.1 | [4.7, 5.6] | 5.2 | [4.7, 5.8] | 5.2 | [4.7, 5.7] | ||||
| CD4 percentage (n = 650) | 8 | [2, 15] | 9 | [3, 17] | 8 | [2, 16] | ||||
| Blood platelets (cells/mm3) (n = 591) | 306500 | [227500, 395000] | 302000 | [224000, 384000] | 304000 | [227000, 390000] | ||||
| White blood cell count (cells/mm3) (n = 618) | 7000 | [5270, 9300] | 7510 | [5500, 10300] | 7300 | [5410, 10000] | ||||
| Absolute neutrophil count (cells/mm3) (n = 585) | 3080 | [2180, 4218] | 3325 | [2409, 4981] | 3276 | [2270, 4633] | ||||
| Absolute lymphocyte count (cells/mm3) (n = 616) | 2380 | [1550, 4120] | 2550 | [1584, 4670] | 2465 | [1571, 4359] | ||||
| Anemia (WHO criteria) | ||||||||||
| No or mild anemia | 129 | (48%) | 174 | (51%) | 303 | (50%) | ||||
| Moderate or severe anemia | 140 | (52%) | 164 | (49%) | 304 | (50%) | ||||
Abbreviations: ART, Antiretroviral treatment; SD, Standard deviation; CDC, Centers for Disease Control and Prevention; WHO, World Health Organization
a Except if specified otherwise
b According to Thai weight and height reference values for children [18]
c Anemia status according on WHO criteria adjusted on sex and age [19]
Fig 1Cumulative incidence of loss to follow-up, with death and referral to another hospital accounted for as competing events.
Association between baseline and time-dependent characteristics and loss to follow-up.
| Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|
| Variables | SHR | (95% CI) | aSHR | (95% CI) | ||
| Female | 1.09 | (0.83–1.45) | 0.53 | |||
| Age ≥7 years | 1.58 | (1.19–2.09) | 0.002 | |||
| Country of birth other than Thailand | 1.51 | (0.63–3.57) | 0.35 | |||
| Born in district hospital | 1.10 | (0.76–1.58) | 0.62 | |||
| Living with relatives (versus in an orphanage) | 2.58 | (1.27–5.22) | 0.008 | |||
| Height-for-age Z-scores <-2 SD | 0.87 | (0.63–1.20) | 0.40 | |||
| Weight-for-age Z-scores <-2 SD | 0.83 | (0.52–1.34) | 0.45 | |||
| ART initiation at or after enrollment to cohort | 1.21 | (0.88–1.67) | 0.23 | |||
| CD4 ≤10% | 1.03 | (0.74–1.42) | 0.87 | |||
| HIV RNA load >100,000 copies/mL | 0.93 | (0.66–1.32) | 0.69 | |||
| CDC stage (class B or C) | 0.81 | (0.61–1.07) | 0.14 | |||
| Moderate or severe anemia (WHO criteria) | 0.82 | (0.59–1.14) | 0.23 | |||
| Age ≥13 years | 2.81 | (1.93–4.10) | <0.001 | 3.14 | (2.06–4.78) | <0.001 |
| Height-for-age Z-scores <-2 SD | 0.51 | (0.34–0.77) | 0.001 | 0.63 | (0.42–0.96) | 0.03 |
| Weight-for-age Z-scores <-2 SD | 0.44 | (0.25–0.77) | 0.004 | 0.43 | (0.24–0.77) | 0.005 |
| CD4 ≤25% | 1.04 | (0.75–1.45) | 0.80 | |||
| HIV RNA load >400 copies/mL | 1.31 | (0.92–1.87) | 0.13 | |||
| CDC stage (class B or C) | 0.88 | (0.62–1.25) | 0.48 | |||
| Moderate or severe anemia (WHO criteria) | 0.63 | (0.41–0.97) | 0.03 | |||
| ART interruption | 2.60 | (1.17–5.80) | 0.02 | 2.57 | (1.12–5.91) | 0.03 |
| At least one switch of regimen | 1.34 | (0.93–1.93) | 0.11 | |||
Abbreviations: LTFU, Loss to follow-up; n, Number of children who were LTFU in the category; N, Number of children in the category; SHR, Subhazard ratio; aSHR, Adjusted subhazard ratio; CI, Confidence intervals; ART, Antiretroviral treatment; SD, Standard deviation; CDC, Centers for Disease Control and Prevention; WHO, World Health Organization
a Competing events: death, referral to another hospital; adjusting for calendar year from ART initiation and region in Thailand; missing baseline values imputed using the nearest available data within 1 year before or within 15 days after ART initiation, and missing values for time-dependent variables imputed using linear interpolation based on the previous and following observed values within 1 year
b According to Thai weight and height reference values for children [18]
c Anemia status based on hemoglobin level, sex, and age following WHO criteria [19]
d ART interruption considered as discontinuation for more than 7 days followed by resumption